p53 Mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3153-3158

  Schneider, Paul M ^a,c,d   Stoeltzing, Oliver ^a,d   Roth, Jack A ^b   Hoelscher, Arnulf H ^a,d   Wegerer, Sieglinde ^a   Mizumoto, Seiichi ^a,e   Becker, Karen ^a   Dittler, Hans J ^a   Fink, Ulrich ^a   Siewert, J Ruediger ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER SURVIVAL; DNA DETERMINATION; DNA SEQUENCE; ENDOSCOPIC BIOPSY; EXON; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SINGLE STRAND CONFORMATION POLYMORPHISM; UNITED STATES; WESTERN EUROPE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; EXONS; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033875562     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Sjogren, R. W., Jr., and Johnson, L. F. Barrett's esophagus: a review. Am. J. Med., 74: 313-321, 1983.
2. Spechler, S. J., and Goyal, R. K. Barrett's esophagus. N. Engl. J. Med., 315: 362-371, 1986.
3. Reid, B. J. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol. Clin. North Am., 20: 817-834, 1991.
4. Hamilton, S. R., and Smith, R. R. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am. J. Clin. Pathol., 87: 301-312, 1987.
5. Drewitz, D. J., Sampliner, R. E., and Garewal, H. S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am. J. Gastroenterol., 92: 212-215, 1997.
6. Altorki, N. K., and Skinner, D. B. Adenocarcinoma in Barrett's esophagus. Semin. Surg. Oncol., 6: 274-278, 1990.
7. Pera, M., Cameron, A. J., Trastek, V. F., Carpenter, H. A., and Zinsmeister, A. R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology, 104: 510-513, 1993.
8. Blot, W. J. Esophageal cancer trends and risk factors. Semin. Oncol., 21: 403-410, 1994.
9. Haggitt, R. C., Tryzelaar, J., Ellis, F. H., et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am. J. Clin. Pathol., 70: 1-5, 1978.
10. Hameeteman, W., Tytgat, G. N., Houthoff, H. J., et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology, 96: 1249-1256, 1989.
11. Rabinovitch, P. S., Reid, B. J., Haggitt, R. C., et al. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab. Investig., 60: 65-71, 1989.
12. Reid, B. J., Blount, P. L., Rubin, C. E., et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology, 102: 1212-1219, 1992.
13. Reid, B. J., Barrett, M. T., Galipeau, P. C., et al. Barrett's esophagus: ordering the events that lead to cancer. Eur. J. Cancer Prev., 2: 57-65, 1996.
14. Blount, P. L., Ramel, S., Raskind, W. H., et al. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res., 51: 5482-5486, 1991.
15. Ramel, S., Reid, B. J., Sanchez, C. A., et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology, 102: 1220-1228, 1992.
16. Casson, A. G., Mukhopadhyay, T., Cleary, K. R., et al. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res., 51: 4495-4499, 1991.
17. Schneider, P. M., Casson, A. G., Levin, B., et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J. Thorac. Cardiovasc. Surg., 111: 323-331, 1996.
18. Casson, A. G., Kerkvliet, N., and O'Malley, F. Prognostic value of p53 protein in esophageal adenocarcinoma. J. Surg. Oncol., 60: 5-11, 1995.
19. Sauter, E. R., Keller, S. M., and Erner, S. M. p53 correlates with improved survival in patients with esophageal adenocarcinoma. J. Surg. Oncol., 58: 269-273, 1995.
20. Hardwick, R. H., Barham, C. P., Ozua, P., et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma: no correlation with prognosis. Eur. J. Surg. Oncol., 23: 30-35, 1997.
21. Coggi, G., Bosari, S., Roncalli, M., et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlations. Cancer (Phila.), 79: 425-432, 1997.
22. Hölscher, A. H., Bollschweiler, E., Bumm, R., et al. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery, 118: 845-855, 1995.
23. Hermanek, P., Henson, D. E., Hutter, R. V. P., and Sobin, L. H (eds.). UICC TNM Supplement, pp. 9-14. Berlin: Springer-Verlag, 1993.
24. Hölscher, A. H., Bollschweiler, E., Schneider, P. M., and Siewert, J. R. Early adenocarcinoma in Barrett's esophagus. Br. J. Surg., 84: 1470-1473, 1997.
25. Bumm, R., Hölscher, A. H., Feussner, H., Tachibana, M., Bartels, H., and Siewert, J. R. Endodissection of the thoracic esophagus. Technique and clinical results in transhiatal esophagectomy. Ann. Surg., 218: 97-104, 1993.
26. Maruyama, K., Okabayashi, K., and Kinoshita, T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J. Surg., 11: 418-425, 1987.
27. Hermanek, P., Henson, D. E., Hutter, R. V. P., and Sobin, L. H (eds.). UICC TNM Klassifikation, pp. 9-14. Berlin: Springer Verlag, 1992.
28. Riddell, R. H. Dysplasia and regression in Barrett's epithelium. In: S. J. Spechler and R. K. Goyal (eds.). Barrett's Esophagus, pp. 224-229. New York: Elsevier Science Publishing Co., Inc., 1985.
29. Williamson, W. A., Ellis, F. H., Jr., Gibb, S. P., et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch. Intern. Med., 151: 2212-2216, 1991.
30. Nigro, J. M., Baker, S. J., Preisinger, A. C., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond.), 342: 705-708, 1989.
31. Lohmann, D. R., Fesseler, B., Putz, B., Reid, U., Boehm, J., Praew, H. W., Wumich, P. H., and Hoefler, H. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res., 53: 5797-5808, 1993.
32. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 187-220, 1958.
33. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Chemother. Rep., 50: 163-170, 1966.
34. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B, 34: 187-220, 1972.
35. Neshat, K., Sanchez, C. A., Galipeau, P. C., et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology, 106: 1589-1595, 1994.
36. Gleeson, C. M., Sloan, J. M., McGuigan, J. A., Ritchie, A. J., and Russell, S. E. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res., 55: 3406-3411, 1995.
37. Nowell, P. C. The clonal evolution of tumor cell populations. Science (Washington DC), 194: 23-28, 1976.
38. Slaughter, D. P., Southwick, H. W., and Smejkal, W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer (Phila.), 6: 963-968, 1954.
39. Bennett, W. P., Hollstein, M., Metcalf, R. A., et al. p53 mutations and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res., 52: 6092-6097, 1992.
40. Younes, M., Lebovitz, R. M., Lechago, L. V., et al. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology, 105: 1637-1642, 1993.
41. Rice, T. W., Goldblum, J. R., Falk, G. W., et al. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. J. Thorac. Cardiovasc. Surg., 108: 1132-1137, 1994.
42. Jones, D. R., Davidson, A. G., Summers, C. L., et al. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann. Thorac. Surg., 57: 598-603, 1994.
43. Duhaylongsod, F. G., Gottfried, M. R., Iglehart, J. D., et al. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann. Surg., 221: 677-683, 1995.
44. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
45. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318-1327, 1993.
46. Johansson, J., Johnsson, F., Walther, B., et al. Adenocarcinoma in the distal esophagus with and without Barrett esophagus. Differences in symptoms and survival rates. Arch. Surg., 131: 708-713, 1996